SpringWorks Therapeutics is a biotechnology business based in the US. SpringWorks Therapeutics shares (SWTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $36.55 – an increase of 7.53% over the previous week. SpringWorks Therapeutics employs 305 staff and has a trailing 12-month revenue of around $135.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $36.55 |
|---|---|
| 52-week range | $20.19 - $53.92 |
| 50-day moving average | $32.82 |
| 200-day moving average | $40.25 |
| Wall St. target price | $68.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-4.67 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $34.71 from 2024-11-13
| 1 week (2024-11-08) | 2.12% |
|---|---|
| 1 month (2024-10-15) | 13.80% |
| 3 months (2024-08-15) | -4.14% |
| 6 months (2024-05-15) | -23.21% |
| 1 year (2023-11-15) | 57.27% |
|---|---|
| 2 years (2022-11-15) | 26.68% |
| 3 years (2021-11-15) | 69.63 |
| 5 years (2019-11-15) | 87.02% |
| Revenue TTM | $135.5 million |
|---|---|
| Gross profit TTM | $35 million |
| Return on assets TTM | -34.28% |
| Return on equity TTM | -59.33% |
| Profit margin | -203.09% |
| Book value | $7.17 |
| Market Capitalization | $2.7 billion |
TTM: trailing 12 months
We're not expecting SpringWorks Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, SpringWorks Therapeutics's shares have ranged in value from as little as $20.1919 up to $53.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SpringWorks Therapeutics's is 0.792. This would suggest that SpringWorks Therapeutics's shares are less volatile than average (for this exchange).
SpringWorks Therapeutics, Inc. , a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.